Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.30

Genmab A/S (NASDAQ:GMAB - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $29.30, but opened at $30.32. Genmab A/S shares last traded at $30.41, with a volume of 35,398 shares changing hands.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. UBS Group raised Genmab A/S from a "neutral" rating to a "buy" rating in a report on Wednesday, December 6th. Morgan Stanley reiterated an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday. Truist Financial reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Genmab A/S presently has an average rating of "Hold" and a consensus price target of $48.50.

Genmab A/S Trading Up 1.2 %

The firm has a market cap of $19.59 billion, a P/E ratio of 30.89, a price-to-earnings-growth ratio of 1.40 and a beta of 0.99. The business has a 50-day moving average of $29.06 and a two-hundred day moving average of $30.82.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The business had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. As a group, equities analysts expect that Genmab A/S will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the stock. First Manhattan Co. bought a new stake in shares of Genmab A/S in the 4th quarter valued at about $26,000. Headlands Technologies LLC acquired a new position in shares of Genmab A/S in the 3rd quarter valued at about $27,000. Pinnacle Bancorp Inc. lifted its stake in shares of Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company's stock valued at $27,000 after purchasing an additional 638 shares during the period. NBC Securities Inc. acquired a new position in shares of Genmab A/S in the 3rd quarter valued at about $37,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Genmab A/S by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company's stock valued at $38,000 after purchasing an additional 498 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.